The editorial, authored by Gabriel Broocks of Helios Medical Center Schwerin and colleagues from Germany, Singapore, and the United States, synthesizes the current state of DMVO research across epidemiology, diagnostics, treatment options, and outcome prediction. Its central message is that DMVO is not a single disease entity. Occlusions differ in vessel diameter, anatomical segment, eloquence of the affected territory, collateral supply, clinical deficit severity, thrombus origin, and procedural accessibility. Primary DMVOs must also be distinguished from secondary distal occlusions that arise through spontaneous or treatment-related thrombus migration after an initially proximal occlusion. Treating all of these presentations as one therapeutic indication, the authors contend, has been a fundamental error in trial design.

Three randomized trials have now tested routine thrombectomy in broadly selected DMVO populations. DISTAL, ESCAPE-MeVO, and the early-terminated DISCOUNT trial did not demonstrate a clinical benefit of endovascular treatment and raised concerns regarding procedure-related harm, including symptomatic intracranial hemorrhage and, in some cohorts, mortality signals. These results sent shockwaves through the stroke community, prompting some to question whether distal thrombectomy should be abandoned altogether. But the story took a dramatic turn with ORIENTAL-MeVO, a trial conducted in Chinese patients with medium-vessel occlusion and moderate-to-severe deficits. Among participants with a National Institutes of Health Stroke Scale score of 6 or higher, endovascular treatment increased 90-day functional independence from 46.6 percent to 58.6 percent, with an adjusted rate ratio of 1.24 and a 95 percent confidence interval of 1.07 to 1.44. Symptomatic intracranial hemorrhage occurred in 4.7 percent of treated patients versus 2.2 percent of controls. This divergent result underscores the influence of trial population, occlusion definition, thrombolysis use, and procedural strategy, and argues powerfully against treating DMVO as a single therapeutic indication.

Neutral treatment effects should not be mistaken for a benign natural history. Across contemporary randomized control groups, between 32 and 53 percent of medically managed patients did not achieve functional independence at 90 days. This proportion exceeded 45 percent in DISTAL, at 45.3 percent, and in ORIENTAL-MeVO, at 53.4 percent. These control arms represent some of the most robust prospective repositories of outcome data under contemporary medical care, and they show that DMVO frequently results in death or persistent dependency. The observation does not justify indiscriminate thrombectomy, since technical accessibility alone does not establish a treatment indication and expected benefit must exceed procedural risk. But it does demonstrate that both routine endovascular treatment as tested and medical treatment alone remain unsatisfactory for many patients, reinforcing the urgent need for better selection and safer or more effective reperfusion strategies.

The trials, therefore, sharpen rather than settle the central question of patient selection, particularly for M2 occlusions, whose anatomical and functional definitions remain heterogeneous. Proximal or dominant M2 branches lie closer to classical large-vessel-occlusion evidence than truly distal M3, A3, or P3 occlusions. Observational data suggest that any benefit of successful reperfusion may concentrate in specific phenotypes. In M2 stroke, the association between recanalization and 90-day functional independence was larger at higher baseline stroke severity, according to a multicenter cohort study published in Neurology. Complementing this, penumbral imaging identified subgroups defined by larger hypoperfusion or penumbral volumes in which reperfusion was associated with better outcome, as reported in the journal Stroke. These hypothesis-generating findings support imaging- and severity-informed selection rather than a purely anatomical indication, suggesting that the future of DMVO treatment lies not in the catheter itself but in the brain imaging that determines who receives it.

Several contributions to the Research Topic address the delicate balance between reperfusion efficacy and vessel safety. A systematic review and meta-analysis by Loh and colleagues found that combined stent-retriever and aspiration techniques were associated with higher first-pass reperfusion and lower symptomatic intracranial hemorrhage than single-device approaches, although final functional outcomes were similar. These retrospective data concern technique selection among treated patients and do not establish superiority of thrombectomy over medical treatment. The ONE-SEG technique of Hamada and colleagues, which combines limited deployment of the distal basket segment of a stent retriever with aspiration, achieved high reperfusion rates in a small M2 cohort, with outcomes differing substantially between primary and secondary M2 occlusions. On the engineering side, Ishiguro and colleagues linked reduced radial and axial device forces to less vessel deformation on bench testing and a lower frequency of post-procedural subarachnoid hemorrhage. When the expected absolute benefit is small, such reductions in procedural trauma may prove decisive.

Newer low-profile devices may alter the procedural risk-benefit balance, although their clinical relevance remains uncertain. In a retrospective series, the small-bore Red43 distal aspiration catheter showed high target-vessel trackability and reperfusion rates without symptomatic intracranial hemorrhage, perforation, or dissection. For stent-retriever thrombectomy, the randomized DISTALS trial specifically evaluated the radially adjustable low-profile Tigertriever 13 and reported favorable technical efficacy and safety, though these device-specific angiographic findings should not be equated with established functional benefit. A complementary strategy is local pharmacological reperfusion. The RESCUE-TNK trial was designed to evaluate intra-arterial tenecteplase for primary or secondary medium-vessel occlusions considered unsuitable for mechanical clot retrieval. These developments support comparative evaluation of device- and drug-specific reperfusion strategies using clinical rather than purely angiographic endpoints, a shift that could fundamentally change how the field measures success.

Anatomical and clinical heterogeneity is equally central to the DMVO puzzle. In an endovascular-treated cohort of isolated posterior cerebral artery occlusions, van Landeghem and colleagues observed that P1 occlusions produced more severe and broader deficits, whereas P2 occlusions more often caused visual syndromes that may be underrepresented by the NIHSS. Deep infarction remained common despite angiographic reperfusion, a finding that challenges the assumption that successful recanalization always translates into tissue salvage. The case series by Xu and Yang illustrates the diagnostic complexity of bilateral paramedian thalamic infarction and the artery of Percheron, in which a unilateral fetal-type posterior cerebral artery may serve as an anatomical clue and treatment targeted upstream large-vessel pathology rather than the perforator itself. The Research Topic also examines markers of adverse outcome after reperfusion. A meta-analysis by Wu and colleagues associated early venous filling during thrombectomy with higher intracranial hemorrhage risk and lower functional independence, a potentially useful real-time warning sign that still requires standardized definition and prospective validation.

The next phase of DMVO research should move beyond a binary debate over whether distal thrombectomy is safe and effective. Future studies should identify treatment-responsive phenotypes by integrating disabling deficit, eloquent tissue involvement, occlusion segment, collateral and perfusion status, thrombus characteristics, procedural accessibility, and predicted device-related risk, while separating primary from secondary DMVO. Outcome measures should capture vision, language, cognition, fine motor function, and quality of life in addition to the modified Rankin Scale, the standard but admittedly blunt instrument for measuring stroke recovery. The neutral randomized trials appropriately challenge indiscriminate treatment, and together with the positive ORIENTAL-MeVO signal, they sharpen two essential questions: which carefully selected patients can achieve a meaningful net benefit from rapid complete reperfusion, and how future trials should be designed to identify the patients most likely to benefit from endovascular treatment. For now, the answer lies not in the catheter but in the convergence of advanced imaging, refined phenotyping, and a willingness to abandon the one-size-fits-all approach that has defined the field for too long.

Subject of Research: Endovascular treatment and patient selection in distal medium vessel occlusion stroke

Article Title: Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction

Article References: Broocks, G., Papanagiotou, P., Yeo, L. L. L., Gopinathan, A., Raz, E., & Meyer, L. (2026). Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction. Frontiers in Stroke, 5, Article 1967379. https://doi.org/10.3389/fstro.2026.1967379

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1967379

Keywords: stroke, mechanical thrombectomy, medium vessel occlusion, endovascular treatment, randomized trials, M2 occlusion, penumbral imaging, intracranial hemorrhage, reperfusion, patient selection, NIHSS, functional independence